News New auction for 23andMe sought with $305m bid from ex-CEO A new auction for bankrupt genetic testing company 23andMe looks likely after former CEO Anne Wojcicki offered to outbid Regeneron.
News 23andMe founder isn't giving up her bid to regain control 23andMe founder Anne Wojcicki is hoping to make a fresh bid for the genetic testing firm, riding out a takeover deal with Regeneron.
News Regeneron swoops on genetic testing firm 23andMe DNA testing company 23andMe looks destined to be taken over by a pharma company, as Regeneron agrees a $256 million acquisition deal.
News 23andMe files for bankruptcy protection DNA testing specialist 23andMe has filed for bankruptcy, prompting the resignation of co-founder and chief executive Anne Wojcicki.
News Troubled 23andMe is exploring a sale of the business Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.
News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.